866-997-4948(US-Canada Toll Free)

Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 48 Pages


GlobalData, the industry analysis specialist, has released its new report, “Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Mutiple Sclerosis therapeutics market and pipeline The report identifies the key trends shaping and driving the global Mutiple Sclerosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Multiple Sclerosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData has estimated the global Mutiple Sclerosis therapeutics market to be valued at $8.2 billion in 2009. It is expected to increase to $20.2 billion with a Compound Annual Growth Rate (CAGR) of 12% by 2017. There is a high unmet need in the current Mutiple Sclerosis therapeutics market in terms of both safety and efficacy profile. New high potential drugs Mutiple Sclerosis therapeutics are expected to come in the market after 2017 

Scope

  • The report provides information on the key drivers and challenges of the Mutiple Sclerosis therapeutics market. Its scope includes:
  • Annualized global Mutiple Sclerosis therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major classes such as nerve growth factor and doparmegenic neurons loss inhibitor
  • Analysis of the current and future competition in the global Mutiple Sclerosis therapeutics market. Key market players covered are Novartis, Biogen Idec, Merck Serono and Sanofi Aventis.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Mutiple Sclerosis therapeutics market.
Reasons to buy

  • The report will enhance your decision making capability. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Mutiple Sclerosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Mutiple Sclerosis market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global Mutiple Sclerosis market landscape? - Identify, understand and capitalize.
Table of Content

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Multiple Sclerosis Therapeutics: Introduction 5
2.1 Overview 5
2.1.1 Epidemiology: 5
2.1.2 Symptoms: 5
2.1.3 Diagnosis 6
2.2 GlobalData Pipeline Report Guidance 6

3 Multiple Sclerosis Therapeutics: Market CharacterizationOverview 7
3.1 Multiple Sclerosis Therapeutics Market Size 7
3.2 Multiple Sclerosis Therapeutics Market Forecast and CAGR 7
3.3 Drivers and Barriers for Multiple Sclerosis Therapeutics Market 9
3.3.1 Drivers for Multiple Sclerosis Market 9
3.3.2 Barriers for Multiple Sclerosis Market 9
3.4 Opportunity and Unmet Need 10
3.5 Key Takeaway 11

4 Multiple Sclerosis Therapeutics: Competitive Assessment 12

4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Multiple Sclerosis Therapeutics Market 13
4.3.1 Copaxone (Glatiramer Acetate) 13
4.3.2 Avonex/Rebif (Interferon Beta) 14
4.3.3 Tysabri (Natalizumab) 15
4.3.4 Novantrone (Mitoxantrone) 16
4.3.5 Betaseron/Betaferon 17
4.3.6 Extavia (Interferon beta-1b) 18
4.4 Recent Launches in the Muliple Sclerosis Therapeutics Market 19
4.4.1 Ampyra (dalfampidine) 19
4.4.2 Gilenya (fingolimod) 20
4.5 Key Takeaway 21

5 Multiple Sclerosis Therapeutics: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 22
5.2.1 Technology Trends Analytic Framework 22
5.3 Multiple Sclerosis Therapeutics Promising Drugs Under Clinical Development 24
5.4 Molecule Profile for Promising Drugs Under Clinical Development or Filing Stage for Multiple Sclerosis 25
5.4.1 Mylinax (Cladribine Oral Formulation) 25
5.4.2 Teriflunomide 26
5.4.3 BG-12 26
5.4.4 Laquinimod 27
5.5 Multiple Sclerosis Therapeutics Market Clinical Pipeline by Mechanism of Action 28
5.6 Multiple Sclerosis Therapeutics Pipeline Pipeline by Clinical Phases of Development 29
5.6.1 Multiple Sclerosis Therapeutics Regulatory and Phase III Clinical Pipeline 30
5.6.2 Multiple Sclerosis Therapeutics Phase II Clinical Pipeline 31
5.6.3 Multiple Sclerosis Therapeutics Phase I Clinical Pipeline 33
5.6.4 Multiple Sclerosis Therapeutics Pre-Clinical Pipeline 34
5.6.5 Multiple Sclerosis Therapeutics Discovery Pipeline 35
5.7 Key Takeaway 35

6 Multiple Sclerosis Therapeutics: Implications for Future Market Competition 36

7 Multiple Sclerosis Therapeutics: Future Players in Multiple Sclerosis Therapeutics Market 37

7.1 Introduction 37
7.2 Biogen idec 38
7.2.1 Overview 38
7.2.2 CNS Portfolio 38
7.2.3 Multiple Sclerosis Product Portfolio 39
7.3 Merck Serono 40
7.3.1 Overview 40
7.3.2 CNS Portfolio 40
7.3.3 Multiple Sclerosis Product Portfolio 41
7.4 Sanofi-aventis 42
7.4.1 Overview 42
7.4.2 CNS Portfolio 42
7.5 Novartis 42
7.5.1 Company Overview 42
7.5.2 Business Overview 43

8 Multiple Sclerosis Therapeutics: Appendix 44

8.1 Research Methodology 44
8.1.1 Coverage 44
8.1.2 Secondary Research 44
8.1.3 Forecasting 44
8.1.4 Primary Research 47
8.1.5 Expert Panel Validation 47
8.2 Contact Us 47
8.3 Disclaimer 47
8.4 Sources 48

List of Table


Table 1: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2000-2009 7
Table 2: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2009-2017 8
Table 3: Major Market Products Comparison in Multiple Sclerosis Therapeutics Market, 2009 21
Table 4: Multiple Sclerosis Therapeutics Most Promising Drugs Under Clinical Development, 2009 24
Table 5: Multiple Sclerosis Therapeutics Phase III Clinical Pipeline, 2009 30
Table 6: Multiple Sclerosis Therapeutics Phase II Clinical Pipeline, 2009 31
Table 7: Multiple Sclerosis Therapeutics Phase I Clinical Pipeline, 2009 33
Table 8: Multiple Sclerosis Therapeutics Pre-clinical Pipeline, 2009 34
Table 9: Multiple Sclerosis Therapeutics Pre-clinical Pipeline, 2009 35
Table 10: Biogen Neurologic Disorder Marketed Products, 2009 38
Table 11: Biogen Neurologic Disorder Pipeline Products, 2009 38
Table 12: Merck Serono Neurologic Disorder Marketed Products, 2009 40
Table 13: Merck Serono Neurologic Disorder Pipeline Products, 2009 40
Table 14: Sanofi-aventis Neurologic Disorder Marketed Products, 2009 42
Table 15: Sanofi-aventis Neurologic Disorder Pipeline Products, 2009 42
Table 16: Novartis Multiple Sclerosis Pipeline 43

List of Chart


Figure 1: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2001-2009 7
Figure 2: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Multiple Sclerosis Therapeutics Market, 2009 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Multiple Sclerosis, 2009 13
Figure 5: Technology Trends Analytic Framework for the Multiple Sclerosis Therapeutics Pipeline, 2009 23
Figure 6: Technology Trends Analytic Framework of the Multiple Sclerosis Therapeutics Pipeline Description, 2009 23
Figure 7: Multiple Sclerosis Therapeutics Market Clinical Pipeline by Mechanism of Action, 2009 28
Figure 8: Multiple Sclerosis Therapeutics Pipeline by Phase of Clinical Development, 2009 29
Figure 9: Implications for Future Market Competition in the Multiple Sclerosis, 2009 36
Figure 10: Multiple Sclerosis Therapeutics Market Clinical Pipeline by Company, 2009 37
Figure 11: GlobalData Market Forecasting Model 46

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *